Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

McMaster University

$17,500.00

Statin-induced myopathy via the NOD-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome

EF 2014-15

Résumé
Over the last decade, the cardiovascular disease death rate in Canada has declined by 40%, largely due to research advances in prevention efforts and drug therapies. As such, statins (such as LipitorTM) have become one of the most widely prescribed cardiovascular medications globally and in Canada. Statins act to lower bad cholesterol (LDL) levels to reduce the risk of heart attacks and stroke. Recently, the American Heart Association has published new guidelines on statin use. This change will push the number of statin users to over 60 million in the US, with other countries, including Canada, to follow suit. Statins have well-described side effects. The major side effect of statins is myopathy, which ranges from muscle weakness and pain to deadly muscle destruction. More importantly, muscle pain reduces the adherence of patients on statin therapy, increasing their risk of developing cardiovascular disease. Additionally, there has been a lot of interest in the recent connection between statins and diabetes. Our lab has recently discovered that statins can activate the inflammasome (an immune response) to impair how insulin works in fat tissues. This provided one of the first potential mechanisms linking statins to diabetes. Based on our recent discovery, we believe that the inflammasome is a key player in the adverse effects of statins in muscle. Members of our lab have worked on muscle myopathy for over 15 years and we are well positioned to test if the inflammasome is involved in statin-induced myopathy. The proposed research will be highly relevant to a large percentage of Canadians, and may set the stage for new or combination therapies that reduce a serious adverse effect, but still allow statins to effectively lower bad cholesterol.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
331378
Name
Li Yujin
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Statin-induced myopathy via the NOD-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Diabetes; Inflammasome; Metabolic Disorders; Metabolism; Myopathy; Statins
Abstract
Over the last decade, the cardiovascular disease death rate in Canada has declined by 40%, largely due to research advances in prevention efforts and drug therapies. As such, statins (such as LipitorTM) have become one of the most widely prescribed cardiovascular medications globally and in Canada. Statins act to lower bad cholesterol (LDL) levels to reduce the risk of heart attacks and stroke. Recently, the American Heart Association has published new guidelines on statin use. This change will push the number of statin users to over 60 million in the US, with other countries, including Canada, to follow suit. Statins have well-described side effects. The major side effect of statins is myopathy, which ranges from muscle weakness and pain to deadly muscle destruction. More importantly, muscle pain reduces the adherence of patients on statin therapy, increasing their risk of developing cardiovascular disease. Additionally, there has been a lot of interest in the recent connection between statins and diabetes. Our lab has recently discovered that statins can activate the inflammasome (an immune response) to impair how insulin works in fat tissues. This provided one of the first potential mechanisms linking statins to diabetes. Based on our recent discovery, we believe that the inflammasome is a key player in the adverse effects of statins in muscle. Members of our lab have worked on muscle myopathy for over 15 years and we are well positioned to test if the inflammasome is involved in statin-induced myopathy. The proposed research will be highly relevant to a large percentage of Canadians, and may set the stage for new or combination therapies that reduce a serious adverse effect, but still allow statins to effectively lower bad cholesterol.
Competitiondate
201412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Li, Yujin
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~